Clinical Trials Logo
  1. Home
  2. MCL
  3. NCT06463691

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

MCL Clinical Trial

Official title:
An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy and Safety of Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

Clinical Trial Summary

This is a an open-label, multi-center, single-arm study to evaluate the efficacy and safety of sonrotoclax, zanubrutinib and CD20mab in untreated MCL patients.

Clinical Trial Description

The benefits of efficacy and survival of immunotherapy regimen in TN MCL is limited, and not all patients are fit for receiving chemotherapy. Considering the balance of toxicity and efficacy, a chemo-free regimen will be a trend in 1L MCL patients. The study is to explore the sonrotoclax, zanubrutinib and CD20mab combination regimen for TN MCL. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06463691
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact Huilai Zhang, MD, PhD
Phone 0086-22-23359337
Email info@tjmuch.com
Status Not yet recruiting
Phase Phase 2
Start date August 2024
Completion date July 2029
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06213636 - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Phase 1/Phase 2
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Recruiting NCT05788289 - A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT03625037 - First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Phase 1/Phase 2
Recruiting NCT06192888 - A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma Phase 1
Recruiting NCT06256484 - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Phase 1
Withdrawn NCT05176691 - HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL Phase 1
Terminated NCT02488512 - Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas Phase 2
Active, not recruiting NCT05214183 - Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT04806035 - Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Phase 1